Source study found
Story checked
Review examines translational bottlenecks for plant-derived anti-inflammatory compounds (opens in a new tab)
news-medical.net · 2026-11-05
Short answer
Not assessedCheck incomplete.
We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.
Share this check
Help improve NewsLink
Tell us what worked or what needs attention in this check.
The story
Review examines translational bottlenecks for plant-derived anti-inflammatory compounds
news-medical.net · 2026-11-05
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Source study identified.
A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.
View article claimsThe source study
Anti-inflammatory drug discovery from medicinal plants: from molecular targets to therapeutic paradigms
Evidence layer
Claim by claim
A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 11Not checkedThe article systematically examines the translational bottlenecks and potential solutions for plant-derived anti-inflammatory compounds.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 2 of 11Not checkedA review led by Professor Weidong Zhang at the School of Pharmacy, Naval Medical University, was published in Volume 2 of the journal Immunity & Inflammation on October 27, 2026.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 3 of 11Not checkedThe review concludes that the key translational bottleneck is whether plant-derived anti-inflammatory compounds can act on a defined molecular target at achievable pharmacological concentrations in diseased tissue and produce disease-relevant effects.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 4 of 11Not checkedThe authors propose a framework that evaluates candidate molecules by chemical properties and active forms, proximal or direct molecular targets, target binding strength, administered dose, disease-relevant mechanisms, and clinical maturity.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 5 of 11Not checkedThe review says downstream pathway changes, transcriptional responses, or phenotypic improvements should not be equated with direct molecular targeting.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 6 of 11Not checkedThe review says many plant-derived compounds influence multiple inflammatory pathways, including NF-κB, MAPK, arachidonic acid metabolism, JAK-STAT, Nrf2, and NLRP3, but broad activity does not prove direct engagement of key targets.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 7 of 11Not checkedThe review argues that dose must be evaluated together with target engagement evidence because free parent compound concentrations after oral administration may be very low or undetectable even when in vitro activity is seen.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 8 of 11Not checkedIn knee osteoarthritis, BCM-95 combined with diclofenac and resveratrol combined with meloxicam are described as having shown adjunctive improvements in pain and function in randomized trials, but without demonstrating mediation through binding to IKKβ or SIRT1.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 9 of 11Not checkedThe review says Tripterygium preparations in rheumatoid arthritis mainly derive from extracts or glycoside mixtures and cannot be directly used as clinical validation of pure triptolide.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 10 of 11Not checkedColchicine is presented as a relatively complete evidence chain, with structural biology support for tubulin binding, clinical trials showing cardiovascular endpoint benefits, and FDA approval in 2023 for reducing the risk of atherosclerotic cardiovascular disease.View evidenceHide evidence
As stated2023
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Claim 11 of 11Not checkedThe review says network pharmacology, multi-omics, activity-guided isolation, molecular networking, virtual screening, artificial intelligence, organoids, organ-on-a-chip models, and delivery platforms such as extracellular vesicles and biomimetic nanocarriers can help research but cannot replace target binding experiments or prospective validation.View evidenceHide evidence
Not checked
A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Anti-inflammatory drug discovery from medicinal plants: from molecular targets to therapeutic paradigms
Immunity & Inflammation · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, PubMed · 16 candidate papers
Anti-inflammatory drug discovery from medicinal plants: from molecular targets to therapeutic paradigms
Immunity & Inflammation · 2026 · Crossref
Phytochemical Screening, Pharmacological Evaluation, and Exploratory In Silico Analysis of Emilia sonchifolia Extract and Solvent Fractions.
Cell Biochemistry and Function · 2026 · PubMed
Antioxidant and Anti-Inflammatory Phytochemicals for the Treatment of Inflammatory Bowel Disease: A Systematic Review
Applied Sciences · 2024 · Crossref
Phytochemicals at the PPAR-NF-κB Interface: A Structured Narrative Review of Receptor Pharmacology, Inflammatory Signaling, and Translational Barriers.
PPAR Research · 2026 · PubMed
Pharmacokinetics, Target Engagement of an Immunoproteasome Subunit Low-Molecular-Mass Polypeptide2 (LMP2) Inhibitor AR-01 and Its Anti-Alzheimers Effects in Rodents
Crossref
Hyperforin as a Multifunctional Specialized Metabolite of Natural Origin for Chronic Diseases: From Molecular Mechanisms to Clinical Translation.
Current Issues in Molecular Biology · 2026 · PubMed
And 10 more candidates considered.